Central Line–Associated Bloodstream Infections in Intensive Care Units
Surveillance results: 2015-2016

From April 1^st, 2015, to March 31^st, 2016, 66 intensive care units (ICUs) took part in surveillance of central line–associated bloodstream infections (CLABSIs), for a combined total of 128,035 catheter-days (Table 1). Participating ICUs reported 150 CLABSIs in 139 patients. Incidence rates are 0.70 per 1,000 catheter-days in teaching adult ICUs, 0.42 in non-teaching adult ICUs, 1.95 in pediatric ICUs and 4.15 in neonatal ICUs (including cases with a mucosal barrier...

Carbapenemase-Producing Gram Negative Bacilli (CPGNB) Infections
Surveillance results: 2015-2016

From April 1, 2015, to March 31, 2016, 73 healthcare facilities took part in the surveillance of carbapenemase-producing Gram negative bacilli (CPGNB) infections, for a total of 3,749,277 patient days (Table 1). In total, four CPGNB infections were reported among patients who acquired their strain during a current or previous hospital stay in the reporting facility (categories 1a and 1b). The incidence rate of healthcare-associated CPGNB infection (cat. 1a and 1b) was 0.011 per 10,000 patient...

Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections
Surveillance results: 2015-2016

From April 1, 2015, to March 31, 2016, 89 healthcare facilities participated in the surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, for a combined total of 4,851,752 inpatient days (Table 1). Together, these facilities reported 65 cases of healthcare-associated MRSA bloodstream infections (HA-MRSA-BSI). The incidence rate was 0.13 per 10,000 patient-days. This incidence rate of HA-MRSA-BSI has declined over the past...

Ce programme de surveillance de laboratoire vise à déterminer la proportion de souches de SARM parmi le nombre total de Staphylococcus aureus isolés de spécimens de la peau et des tissus mous de patients provenant de la communauté, à caractériser leur type moléculaire (communautaire, SARM-AC ou hospitalier, SARM-AH), à évaluer la présence du gène de la toxine PVL et à déterminer leur profil de sensibilité aux antibiotiques.

Trente-sept installations représentatives de la province ont été ciblées afin qu’elles fassent parvenir au Laboratoire de santé publique du Québec (LSPQ) leurs souches de SARM issues des IPTMC isolées du 1^er avril au 2 mai 2015. Le LSPQ a réalisé l’antibiogramme pour 11 antibiotiques, la recherche de la toxine PVL par réaction en chaine...